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Yellow fever vaccination: estimating coverage
Recent decades have witnessed an unprecedented 
emergence of epidemic arbovirus diseases, including 
yellow fever.1 The yellow fever outbreak that started in 
Angola in 2016 developed into the largest and most 
widespread outbreak of yellow fever reported in Africa 
in more than 20 years, leading to depletion of all yellow 
fever vaccine stocks.2 The outbreak also resulted in 
the first documented importation of yellow fever into 
Asia.3 Furthermore, since late 2016, yellow fever has 
caused outbreaks in southeastern Brazil close to the 
most populated areas of South America, with Rio de 
Janeiro state hosting nearly 16 million people.4 Relying 
on reactive vaccination campaigns will inevitably result 
in preventable deaths5 and hence, the mainstay for 
yellow fever control remains adequate vaccine coverage. 
To achieve high vaccination coverage on a long-term 
basis, the best strategy is to incorporate yellow fever 
vaccination into routine infant immunisations and 
to perform catch-up campaigns in the remaining 
population. According to WHO, a vaccine coverage of 
at least 80% would be necessary to prevent and control 
such outbreaks.6 As such, I welcome the analysis by Freya 
Shearer and colleagues7 in The Lancet Infectious Diseases 
that attempted to estimate vaccine coverage from 1970 
to 2016 and calculate the number of individuals to be 
vaccinated to achieve the 80% population coverage 
required for each region to support WHO’s Global 
Strategy to Eliminate Yellow Fever Epidemics.
Shearer and colleagues tracked each age cohort 
(from ages 0 to 99 years) in every district in countries 
with yellow fever transmission from their birth year 
through to 2016, updating the coverage level whenever 
a routine, preventive, or outbreak response campaign 
was done. The proportion vaccinated for each age 
cohort was calculated under three vaccination-targeting 
scenarios. To estimate population-wide vaccination 
under each scenario, the weighted mean proportion 
vaccinated across all age cohorts was calculated, 
weighted by population size and taking into account 
a bias correction for each country and year based on 
ratios derived from estimates of mean coverage for the 
diphtheria-tetanus-pertussis–containing vaccine from 
the Global Burden of Disease Study and administratively 
reported estimates from WHO/UNICEF. Because the 
estimates were not derived from a statistical model, 
estimates of uncertainty were not provided; instead, 
the three scenarios provide some indication of the 
uncertainty around those data.
Shearer and colleagues report overall substantial 
increases in yellow fever vaccine coverage since 1970, 
with vaccination coverage higher in Latin America than 
in Africa. However, notable gaps in vaccination coverage 
within yellow fever risk zones remain. Population 
vaccination coverage in countries within risk zones ranged 
from a maximum of 100% in parts of Amazonas State, 
Brazil, to 0% coverage in parts of central and east Africa 
(where routine infant immunisation programmes have 
not yet been introduced). Increased coverage was recently 
achieved overall in west and central Africa because large 
preventive campaigns supported by the Yellow Fever 
Initiative and the GAVI Alliance were implemented in 
2006. Important gaps were apparent within the risk 
zones of Africa, including large areas of central and east 
Africa and parts of Nigeria, Niger, Sierra Leone, Liberia, 
and Guinea-Bissau. In Latin America, low coverage was 
estimated for Guyana, Suriname, French Guiana, and 
Colombia. Coverage was particularly high in Brazil during 
the 1970s and 1980s, decreased slightly in the 1990s, 
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and was again very high in most parts of the country by 
2016. However, the authors estimated lower levels of 
vaccination coverage at the eastern edge of the risk zone 
in Brazil for 2016, including within the state of Minas 
Gerais, where a yellow fever outbreak arose in December, 
2016. Country-level estimates of yellow fever vaccination 
coverage by age group in 2016 highlight the progress of 
routine infant immunisation programmes in protecting 
children and young adults on both continents, but they 
also revealed coverage gaps in adult populations for most 
countries. Angola, Cameroon, Guinea, Senegal, Togo, 
Paraguay, Bolivia, and Brazil were exceptions to this, with 
moderate-to-high coverage estimated across all age 
groups.
This study provides an unprecedented wealth of data, 
which includes sets of coverage maps, detailed tables, 
and estimates of the number of individuals requiring 
vaccination. Using the estimates of the proportion 
of individuals vaccinated for each district, other 
researchers can recalculate the number of individuals 
requiring vaccination to reach any new threshold. 
The data provided on coverage by age groups is of 
particular additional interest for policy makers and 
epidemiologists. The actual risk based on population 
immune and non-immune estimates combined with 
published criteria on transmission risk8 will determine 
where action is needed, and how to prioritise countries 
on the basis of the level of risk. Documentation of yellow 
fever vaccine coverage over the past decades to the 
present time has many benefits: (1) to document the 
quality of national vaccination programmes over time, 
(2) to provide data to study why some areas had yellow 
fever outbreaks in the past and anticipate outbreaks in 
the future, (3) to set targets for countries to achieve 
higher coverage rates, and (4) to guide planning of 
future vaccination strategies, emergency stockpiling, 
and manufacturing surge capacity.
From the 2016 outputs, Shearer and colleagues 
estimate that 383·6–461·4 million individuals still 
require supplementary vaccination within at-risk 
districts globally to achieve the 80% population 
coverage threshold recommended by WHO to prevent 
outbreaks; the vast majority of those individuals reside 
in Africa. However, these figures are far higher than the 
annual production of yellow fever vaccines. The present 
annual yellow fever vaccine production from all six of 
the world’s manufacturers is only about 80 million doses 
per year, and the global supply of immediately available 
yellow fever vaccine is only about 5–6 million doses.9 
The small number of producers, and the manufacturing 
process requiring embryonated chicken eggs limit 
the amount of vaccine available.10 Over the coming 
decade, vaccine manufacturers are expected to scale up 
production to meet the global demand. WHO estimates 
the global demand to be as high as 1·38 billion doses 
over the next decade—an amount needed to cover 
childhood immunisation programmes, catch-up and 
supplementary programmes, and stockpiling.6 Meeting 
this demand will require increases in vaccine production, 
particularly in the next 5 years.
The total population living in countries with 
Aedes mosquitoes is estimated to be more than 
3 billion people. Although highly populated Asia has 
not witnessed a yellow fever outbreak so far, despite 
the wide distribution of receptive Aedes mosquitoes, the 
increasing travel volume between yellow fever endemic 
areas and Asia11 and the first documented importation 
of yellow fever from Angola to China underpins the 
potential threat.3 Therefore stockpiling and contingency 
plans need to be developed for Asia. Furthermore, 
during the African outbreak in 2016, more unvaccinated 
travellers with yellow fever have been reported than in 
the past 50 years, showing that a substantial number of 
travellers are still able to circumvent the International 
Health Regulations. Absent or erratic control of proof 
of yellow fever vaccination at entry,12 falsified vaccine 
certificates, flawed risk assessments in travel medicine 
clinics,13 changing travel patterns and attitudes of 
travellers,14,15 and inadequate information by travel 
medicine providers16 have led to preventable cases 
of yellow fever in travellers, which contributes to the 
spread into new areas. Although the pre-emptive 
protection of endemic populations should be the main 
thrust, efforts should also be enhanced to contain 
outbreaks rapidly and to stop international spread.6
For decades we have had the tools at hand to control 
yellow fever, and with Shearer and colleagues’ study 
we now also have well researched data to inform 
policy makers where to scale up vaccine coverage and 
to instruct vaccine manufacturers how much to scale 
up supply. The onus is on the world to avoid vaccine 
shortfalls in the future. To this end, a new effort led by 
WHO, the Global Strategy for Eliminating Yellow Fever 
Epidemics, will roll out over the next 5 years.
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Recovery from serious fungal infections should be realisable 
for everyone
Fungal infections are neglected by social and 
political communities. However, they affect more 
than a billion people, resulting in approximately 
11·5 million life-threatening infections and more than 
1·5 million deaths annually.1,2 There have been enormous 
advances in fungal diagnostics and antifungal drug 
development over the past 20 years, but most of the 
world’s population has not yet benefited from these 
advances. The Lancet Infectious Diseases Fungal Infections 
Series brings readers up to date on fungal infections 
and addresses how fungal infection management can 
be integrated into health systems in low-income and 
middle-income countries (LMICs). 
Many medical specialties see patients with 
fungal infections, including general practitioners 
(eg, cutaneous, thrush), paediatricians (almost 
all infections), dermatologists (eg, cutaneous, 
sporotrichosis), ophthalmologists (fungal keratitis), 
oncologists and haematologists (candidiasis and invasive 
mould infections), intensive-care-unit practitioners 
(candidiasis and aspergillosis), internal medicine and 
AIDS physicians (eg, cryptococcosis, histoplasmosis, 
pneumocystis pneumonia), ear, nose, and throat surgeons 
(external otitis, fungal rhinosinusitis), and respiratory 
physicians (all forms of aspergillosis and fungal asthma), 
which complicates provision of holistic education about 
fungal infections. In countries with developed health 
systems, fungal infections are diagnosed and treated, 
although many are still missed and only identified at 
autopsy.3–5 However, in LMICs the absence of diagnostic 
tools and antifungal drugs, plus insufficient training 
of health-care staff, ensures that the mortality and 
morbidity of fungal infections remains unacceptably 
high. Kneale and colleagues6 highlighted many country 
differences in antifungal drug availability and price in 
2015. Amphotericin B is not available to a population 
of 481 million, and where it is available the price varies 
from less than US$1 per day to $171 per day. Flucytosine 
is unavailable to more than 2·9 billion people in more 
than 70% of the countries investigated. Conversely, the 
situation was better for azole drugs. Fluconazole was 
licensed in 88·6% of the countries surveyed, with a daily 
price variation (750–800 mg) of less than $1 to $31. 
Itraconazole was unavailable to more than 78 million 
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